JOSÉ LUIS
REVUELTA HERRERO
Profesor asociado de Ciencias de la Salud
Instituto de Investigación Sanitaria Gregorio Marañón
Madrid, EspañaPublicacións en colaboración con investigadores/as de Instituto de Investigación Sanitaria Gregorio Marañón (17)
2023
-
Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 2855-2882
-
Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy
Frontiers in Oncology, Vol. 13
2022
-
A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application
Frontiers in Oncology, Vol. 12
-
A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital
Frontiers in Public Health, Vol. 10
-
Medication guide for the perioperative management of oral antineoplastic agents in cancer patients
Expert Opinion on Drug Safety, Vol. 21, Núm. 1, pp. 107-119
-
Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients
Journal of Oncology Pharmacy Practice, Vol. 28, Núm. 5, pp. 1259-1263
-
Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App
Frontiers in Oncology, Vol. 12
2021
-
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice
Supportive Care in Cancer, Vol. 29, Núm. 8, pp. 4673-4681
-
Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective
Frontiers in Oncology, Vol. 11
-
Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain
Expert Review of Clinical Pharmacology, Vol. 14, Núm. 2, pp. 249-260
-
Dpyd exome, mrna expression and uracil levels in early severe toxicity to fluoropyrimidines: An extreme phenotype approach
Journal of Personalized Medicine, Vol. 11, Núm. 8
-
Tocilizumab as salvage treatment of refractory pulmonary acute graft-versus-host disease
Journal of Oncology Pharmacy Practice, Vol. 27, Núm. 3, pp. 751-755
2019
-
Drug safety surveillance within a strategy for the management of non-chemotherapy drug-induced neutropenia
International Journal of Clinical Pharmacy, Vol. 41, Núm. 5, pp. 1143-1147
-
Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice
Expert Opinion on Drug Safety, Vol. 18, Núm. 9, pp. 861-868
2018
-
Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice
Journal of Clinical Pharmacy and Therapeutics, Vol. 43, Núm. 6, pp. 906-909
-
Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients
Annals of Pharmacotherapy, Vol. 52, Núm. 1, pp. 11-18
-
Pazopanib-Associated Transient Ischemic Attack
American journal of therapeutics, Vol. 25, Núm. 3, pp. e393-e394